{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:27:20Z","timestamp":1787074040873,"version":"build-2736575974"},"posted":{"date-parts":[[2026,6,30]]},"group-title":"In Review","reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,26]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n To identify baseline gene expression programs associated with recurrence timing in estrogen receptor-positive (ER+) breast cancer (BC) using a multi-state modeling framework.\nMethods\n We analyzed high-risk ER\u2009+\u2009BC patients with surgical tumor specimens profiled using a custom NanoString panel (145 genes). Recurrence was classified as none, early (\\(\\:&lt;\\)5 years after surgery), or late (\\(\\:\\ge\\:\\)5 years). Differential gene expression was assessed using negative binomial regression. Transition-specific risks of recurrence and survival were estimated using semi-Markov multi-state Cox models, with sensitivity analyses conducted under alternative definitions of early and late recurrence.\nResults\n Among 79 patients analyzed, 28% developed recurrence (14 early, 9 late), and all BC-specific deaths occurred following early recurrence. In transition-specific models, higher baseline expression of proliferation-related genes, including\n                  <italic>UBE2C, EZH2, CCNB1, PTTG1<\/italic>\n                  , and\n                  <italic>MKI67<\/italic>\n                  , was consistently associated with increased risk of early recurrence (hazard ratio [HR] range: 1.91\u20132.14; all p\u2009&lt;\u20090.05), whereas\n                  <italic>SNAI2<\/italic>\n                  expression was protective (HR: 0.43; 95% CI: 0.18\u20130.99). In contrast, late recurrence was associated with signaling-related genes such as\n                  <italic>IGF1R, LEF1<\/italic>\n                  , and\n                  <italic>WNT7B<\/italic>\n                  (HR range: 1.52\u20133.40; all p\u2009&lt;\u20090.05). Early recurrence-associated genes showed concordance across differential expression analyses and sensitivity analyses, supporting biological coherence.\nConclusions\n This study identifies a potential proliferative gene assay associated with early recurrence in ER\u2009+\u2009BC, while late recurrence appears linked to distinct signaling pathways. These findings prioritize candidate molecular biomarkers for future validation to improve risk stratification and surveillance.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10159953\/v1","type":"posted-content","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:46:50Z","timestamp":1782848810000},"source":"Crossref","is-referenced-by-count":0,"title":["Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survival"],"prefix":"10.21203","author":[{"given":"Yongzhe","family":"Wang","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Quinones","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kang","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Rugo","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Martinez","sequence":"additional","affiliation":[{"name":"University of Riverside California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Seewaldt","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritro","family":"Nath","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Jones","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","author":"Society AC","year":"2025","unstructured":"Society AC. Cancer Facts & Figs. 2025. Atlanta; 2025. Report No.: 2025."},{"key":"ref2","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2009\u2013\u2009metastatic breast cancer treated with chemotherapy in the United States","author":"Tolaney SM","unstructured":"Tolaney SM, Punie K, Carey LA, Kurian AW, Ntalla I, Sjekloca N et al. Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2009\u2013\u2009metastatic breast cancer treated with chemotherapy in the United States. ESMO Open. 2024\/09\/01;9(9).","journal-title":"ESMO Open"},{"key":"ref3","article-title":"Collecting Long-Term Outcomes in Population-Based Cancer Registry Data: The Case of Breast Cancer Recurrence","author":"Morgan E","unstructured":"Morgan E, O'Neill C, Bardot A, Walsh P, Woods RR, Gonsalves L et al. Collecting Long-Term Outcomes in Population-Based Cancer Registry Data: The Case of Breast Cancer Recurrence. JCO Global Oncology. 2024-October(10)."},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","DOI":"10.3747\/co.21.1563","article-title":"Factors associated with breast cancer mortality after local recurrence","volume":"21","author":"Dent R","year":"2014","unstructured":"Dent R, Valentini A, Hanna W, Rawlinson E, Rakovitch E, Sun P et al. Factors associated with breast cancer mortality after local recurrence. Curr Oncol. 2014;21(3).","journal-title":"Curr Oncol"},{"key":"ref5","article-title":"Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials","author":"Wapnir IL","unstructured":"Wapnir IL, Anderson SJ, Mamounas EP, GeyerJr CE, Jeong J-H, Tan-Chiu E et al. Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials. J Clin Oncol. 2006-May-1;24(13).","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou CM","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:6797. 2000-08-17;406(6797).","journal-title":"Nature"},{"key":"ref7","author":"S\u00f8rlie T","year":"2007","unstructured":"S\u00f8rlie T. Molecular Classification of Breast Tumors. 2007."},{"key":"ref8","first-page":"1","article-title":"Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers","volume":"2019 5","author":"Groenendijk FH","unstructured":"Groenendijk FH, Treece T, Yoder E, Baron P, Beitsch P, Audeh W et al. Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers. npj Breast Cancer 2019 5:1. 2019-04-18;5(1).","journal-title":"npj Breast Cancer"},{"key":"ref9","article-title":"Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes","author":"Parker JS","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2009-3-10;27(8).","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"7403","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis C","year":"2012","unstructured":"Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:7403. 2012-04-18;486(7403).","journal-title":"Nature"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal O","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3).","journal-title":"World J Clin Oncol"},{"key":"ref12","article-title":"Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists","author":"Johnson KS","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. J Breast Imaging. 2021\/01\/26;3(1).","journal-title":"J Breast Imaging"},{"key":"ref13","article-title":"Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race\/Ethnicity in the US","author":"Acheampong T","unstructured":"Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race\/Ethnicity in the US. JAMA Netw Open. 2020\/08\/03;3(8).","journal-title":"JAMA Netw Open"},{"key":"ref14","article-title":"Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative","author":"Aftimos P","unstructured":"Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021\/11\/01;11(11).","journal-title":"Cancer Discov"},{"key":"ref15","first-page":"7418","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Network TCGA","year":"2012","unstructured":"Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:7418. 2012-09-23;490(7418).","journal-title":"Nature"},{"key":"ref16","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","author":"Sparano JA","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018-07-12;379(2).","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-456","article-title":"Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test","volume":"12","author":"Kronenwett R","year":"2012","unstructured":"Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer. 2012;12:1. 2012-10-05;12(1).","journal-title":"BMC Cancer"},{"issue":"2","key":"ref18","article-title":"Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+\/HER2\u2009\u2013\u2009breast cancer patients: results from the GEICAM 9906 trial","volume":"16","author":"Martin M","unstructured":"Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+\/HER2\u2009\u2013\u2009breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res 2014 16:2. 2014-04-12;16(2).","journal-title":"Breast Cancer Res 2014"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8","author":"Wallden B","year":"2015","unstructured":"Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genom. 2015;8:1. 2015-08-22;8(1).","journal-title":"BMC Med Genom"},{"key":"ref20","author":"Sgroi DC","unstructured":"Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM et al. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13\/IL17BR Biomarker. JNCI: Journal of the National Cancer Institute. 2013\/07\/17;105(14)."},{"key":"ref21","article-title":"Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor\u2013Positive Postmenopausal Breast Cancer Patients in the TEAM Trial","author":"Bartlett JMS","unstructured":"Bartlett JMS, Xu K, Wong J, Pond G, Zhang Y, Spears M et al. Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor\u2013Positive Postmenopausal Breast Cancer Patients in the TEAM Trial. Clin Cancer Res. 2024\/04\/15;30(8).","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-025-89274-9","article-title":"Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer","volume":"15","author":"Jones V","year":"2025","unstructured":"Jones V, Yin HH, Yuan Y-C, Wang Y, Li SM, Aljaber D, et al. Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Sci Rep. 2025;15:1. 2025-02-28;15(1).","journal-title":"Sci Rep"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1191\/0962280202SM276ra","article-title":"Multi-state models for event history analysis","volume":"11","author":"Andersen PK","year":"2002","unstructured":"Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11(2):91\u2013115.","journal-title":"Stat Methods Med Res"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter H","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389\u2013430.","journal-title":"Stat Med"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/bimj.200510218","article-title":"Estimation and prediction in a multi-state model for breast cancer","volume":"48","author":"Putter H","year":"2006","unstructured":"Putter H, van der Hage J, de Bock GH, Elgalta R, van de Velde CJ. Estimation and prediction in a multi-state model for breast cancer. Biom J. 2006;48(3):366\u201380.","journal-title":"Biom J"},{"issue":"23\u201324","key":"ref26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/sim.4780132307","article-title":"Penalized likelihood in Cox regression","volume":"13","author":"Verweij PJ","year":"1994","unstructured":"Verweij PJ, Van Houwelingen HC. Penalized likelihood in Cox regression. Stat Med. 1994;13(23\u201324):2427\u201336.","journal-title":"Stat Med"},{"key":"ref27","article-title":"Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis","author":"Gray RJ","unstructured":"Gray RJ. Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis. J Am Stat Assoc. 1992-12-1;87(420).","journal-title":"J Am Stat Assoc"},{"key":"ref28","author":"Therneau TM","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000. xiii, 350 p. p."},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff E","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710\u20138.","journal-title":"Am J Epidemiol"},{"key":"ref30","volume-title":"Dynamic prediction in clinical survival analysis","author":"Houwelingen JCv, Putter H","year":"2012","unstructured":"Houwelingen JCv, Putter H, ProQuest. Dynamic prediction in clinical survival analysis. 1st ed. Boca Raton: CRC; 2012.","edition":"1"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi P","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner T","year":"1996","unstructured":"Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738\u201346.","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5","volume":"36","author":"Dowsett M","year":"2018","unstructured":"Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thurlimann B, et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol. 2018;36(19):1941\u20138.","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08496-y","article-title":"Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours","volume":"21","author":"Bernhardt SM","year":"2021","unstructured":"Bernhardt SM, Dasari P, Glynn DJ, Woolford L, Moldenhauer LM, Walsh D, et al. Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours. BMC Cancer. 2021;21:1. 2021-06-26;21(1).","journal-title":"BMC Cancer"},{"key":"ref35","article-title":"Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study","author":"Buus R","unstructured":"Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL et al. Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. J Clin Oncol. 2021-January-10;39(2).","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00216-w","article-title":"Development and validation for research assessment of Oncotype DX\u00ae Breast Recurrence Score, EndoPredict\u00ae and Prosigna\u00ae","volume":"7","author":"Buus R","year":"2021","unstructured":"Buus R, Szijgyarto Z, Schuster EF, Xiao H, Haynes BP, Sestak I, et al. Development and validation for research assessment of Oncotype DX\u00ae Breast Recurrence Score, EndoPredict\u00ae and Prosigna\u00ae. npj Breast Cancer. 2021;7:1. 2021-02-12;7(1).","journal-title":"npj Breast Cancer"},{"key":"ref37","article-title":"A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer","author":"Paik S","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med. 2004-12-30;351(27).","journal-title":"N Engl J Med"},{"key":"ref38","article-title":"Breast cancer: origins and evolution","author":"Polyak K","unstructured":"Polyak K. Breast cancer: origins and evolution. J Clin Investig. 2007\/11\/01;117(11).","journal-title":"J Clin Investig"},{"key":"ref39","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","author":"Pan H","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017-11-09;377(19).","journal-title":"N Engl J Med"},{"key":"ref40","first-page":"1","article-title":"Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification","volume":"25","author":"Okimoto LYS","year":"2024","unstructured":"Okimoto LYS, Mendonca-Neto R, Nakamura FG, Nakamura EF, Feny\u00f6 D, Silva CT, et al. Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification. BMC Bioinformatics. 2024;25:1. 2024-03-01;25(1).","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-019-5849-0","article-title":"Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series","volume":"20","author":"Picornell AC","year":"2019","unstructured":"Picornell AC, Echavarria I, Alvarez E, L\u00f3pez-Tarruella S, Jerez Y, Hoadley K et al. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics 2019 20:1. 2019-06-03;20(1).","journal-title":"BMC Genomics"},{"key":"ref42","first-page":"1","article-title":"Research-based PAM50 signature and long-term breast cancer survival","volume":"2019 179","author":"Pu M","unstructured":"Pu M, Messer K, Davies SR, Vickery TL, Pittman E, Parker BA et al. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat 2019 179:1. 2019-09-21;179(1).","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"ref43","article-title":"The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions","volume":"27","author":"M\u00fcller BM","year":"2013","unstructured":"M\u00fcller BM, Keil E, Lehmann A, Winzer K-J, Richter-Ehrenstein C, Prinzler J et al. The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLOS ONE Jun 27, 2013;8(6).","journal-title":"PLOS ONE Jun"},{"key":"ref44","article-title":"Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer","author":"Tian S","unstructured":"Tian S, Roepman P, Veer LJvt, Bernards R, Snoo FD, Glas AM et al. Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer. Biomark Insights. 2010-1;5.","journal-title":"Biomark Insights"},{"key":"ref45","article-title":"MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients","author":"Haan JC","unstructured":"Haan JC, Bhaskaran R, Ellappalayam A, Bijl Y, Griffioen CJ, Lujinovic E et al. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. Genes Chromosom Cancer. 2022\/03\/01;61(3).","journal-title":"Genes Chromosom Cancer"},{"key":"ref46","article-title":"A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer","author":"Ma X-J","unstructured":"Ma X-J, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin Cancer Res. 2008\/05\/01;14(9).","journal-title":"Clin Cancer Res"},{"key":"ref47","article-title":"Breast Cancer Index Identifies Early-Stage Estrogen Receptor\u2013Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence","author":"Zhang Y","unstructured":"Zhang Y, Schnabel CA, Schroeder BE, Jerevall P-L, Jankowitz RC, Fornander T et al. Breast Cancer Index Identifies Early-Stage Estrogen Receptor\u2013Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clin Cancer Res. 2013\/08\/01;19(15).","journal-title":"Clin Cancer Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10159953\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10159953\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:07Z","timestamp":1787071267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10159953\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":47,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10159953\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,30]]},"subtype":"preprint"}}